Royalty Pharma plc
RPRX
$45.55
$0.751.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 621.99M | 609.29M | 578.67M | 568.25M | 593.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 621.99M | 609.29M | 578.67M | 568.25M | 593.64M |
| Cost of Revenue | 23.11M | 12.14M | -203.94M | -127.14M | 164.04M |
| Gross Profit | 598.89M | 597.16M | 782.60M | 695.39M | 429.61M |
| SG&A Expenses | 189.60M | 118.50M | 257.30M | 110.71M | 67.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 263.21M | 181.14M | 353.87M | 34.07M | 232.13M |
| Operating Income | 358.78M | 428.16M | 224.80M | 534.18M | 361.51M |
| Income Before Tax | 355.91M | 444.21M | 90.64M | 433.43M | 334.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 355.91M | 444.21M | 90.64M | 433.43M | 334.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -141.71M | -155.99M | -60.46M | -195.08M | -126.14M |
| Net Income | 214.21M | 288.22M | 30.18M | 238.35M | 208.21M |
| EBIT | 358.78M | 428.16M | 224.80M | 534.18M | 361.51M |
| EBITDA | 359.98M | 429.43M | 225.49M | -- | -- |
| EPS Basic | 0.39 | 0.67 | 0.07 | 0.55 | 0.35 |
| Normalized Basic EPS | 0.04 | 0.18 | 0.10 | 0.24 | 0.13 |
| EPS Diluted | 0.39 | 0.67 | 0.07 | 0.55 | 0.35 |
| Normalized Diluted EPS | 0.04 | 0.14 | 0.07 | 0.18 | 0.13 |
| Average Basic Shares Outstanding | 556.00M | 431.89M | 423.51M | 435.48M | 589.00M |
| Average Diluted Shares Outstanding | 556.00M | 559.61M | 562.30M | 578.10M | 589.00M |
| Dividend Per Share | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 |
| Payout Ratio | 44.04% | 33.07% | 308.99% | 40.01% | 44.98% |